Alliance Growers Commences Site Work at Cannabis Biotech Complex
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2018) - Alliance Growers Corp. (CSE: ACG) (FWB: 1LA) (WKN: A2DFYX) ("Alliance" or "the Company") is pleased to announce that its partner in the development of the Cannabis Biotech Complex, WFS Pharmagreen Inc. ("Pharmagreen") has commenced pre-construction ground work. The site work has started for the drilling of three water wells that will supply the Cannabis Biotech Complex commenced on October 31, 2018. Two wells will be used for primary water supply and the third well will be for back up. The water discharge from the irrigation system will be recycled, filtered and reused to minimize the facility's demand on the natural water supply. The entire facility is being engineered with 100% redundancy to ensure there is no disruption to the operations 365 days a year. This state-of-the-art facility is designed to include the latest cannabis cultivation technologies and the latest cannabis-related green technologies.
Commenting on Alliance Grower's Cannabis Biotech Complex progress, Dennis Petke, Alliance Grower's President and CEO, stated, "It has been a long road for Alliance and Pharmagreen to get to this point where we have finally commenced site work on the Cannabis Biotech Complex after more than a year of effort to arrive at this destination. This is a pivotal moment for the Company for two reasons; first to have started the ground work and second to have created the understanding of the investing public of the value of tissue culture plantlets in the cannabis industry to the point where significant equity investment in both Pharmagreen and Alliance is finally starting to gather momentum. This announcement comes on the heels of closing the bulk of ACG's $2,000,000 in private placement financing and sets the stage for Pharmagreen to begin to close on its financing commitments as well. Alliance will be one of the extremely successful cannabis companies that will have sustainable long-term revenue streams that will create value for all stakeholders for many years to come, in an unpredictable market".
About Alliance Growers Corp.
Alliance Growers is a Diversified Global Medical Cannabis Company driven by the Company's 'Four Pillars' Organization Plan - Cannabis Biotech Complex, Strategic ACMPR Investments, CBD Oil Supply and Distribution, and Research and Technology.
Alliance Growers is working with Pharmagreen Biotech Inc. advancing a new business partnership, to jointly develop and operate a 62,000-square foot facility, to be the first of its kind in Western Canada to house a DNA Botany lab, extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general. The proposed Cannabis Biotech Complex's main facility is the Cannabis Biotech Centre which will grow Cannabis plantlets using proprietary tissue culture propagation, specifically utilizing the "Chibafreen Invitro Plant Production System", which allows for more tissue cultured plantlets to be produced in less space and less time.
About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.
WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC PINKS: PHBI) company. WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a proprietary tissue culture process with opportunity to become one of the largest players globally. Pharmagreen's mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of cannabis and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors. For further information on the company progress on the construction of a 62,000 square foot "Cannabis Biotech Complex" please visit www.pharmagreen.ca
If you would like to be added to Alliance Growers' news distribution list, please send your email address to email@example.com.
For more information contact:
CEO, President and Director
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company's corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company's ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete additional suitable acquisitions to further the Company's growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.
The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.